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Introduction
Nuclear factor of activated T cells 5 (NFAT5) is a member of the 
Rel family of transcription factors (TFs) that shares a conserved 
DNA-binding domain with NFATc1-4 and NF-κB. Although 
these TFs all possess a similar DNA-binding sequence (GGAAA), 
NFAT5 lacks a calcineurin-binding domain and is instead highly 
sensitive to salt-induced hypertonicity (1). Thus, NFAT5 was orig-
inally designated as a tonicity-responsive enhancer-binding pro-
tein involved in the protection of cells from hypertonic stress (1). 
Several recent studies indicate that NFAT5 is not solely regulat-
ed by tonicity, but that it can be stimulated in isotonic tissues by 
various tonicity-independent mechanisms (2–5). We and others 
have revealed that NFAT5 promotes the expression of a number of 
proinflammatory genes in macrophages in response to TLR4 acti-
vation and also by stimulating the NF-κB activity (2, 4, 5). Howev-
er, the NFAT5 signature involved in diverse functions of macro-
phages has not yet been systemically analyzed.
Rheumatoid arthritis (RA) is characterized by a massive infil-
tration of a variety of chronic inflammatory cells, including syno-
vial macrophages, into the synovia, leading to the destruction of 
adjacent cartilage and bone (6). Macrophages are one of the most 
abundant cell types in the RA synovia (6–8), and there is ample 
evidence that macrophages are activated in RA and can critical-
ly drive the progression of RA (7, 8). Synovial macrophages are a 
major source of various cytokines and chemokines, including C-C 
motif ligand 2 (CCL2), a key chemokine that controls the migra-
tion and infiltration of monocytes/macrophages into the inflamed 
synovium (6, 9). The number of macrophages in the RA synovia 
has a significant correlation with measures of disease activity, 
including C-reactive protein levels, erythrocyte sedimentation 
rate, swollen joint count, synovial lining vascularity and thickness, 
and radiological severity (10, 11). Moreover, persistent activation 
of certain signaling pathways in synovial macrophages, namely 
NF-κB, STAT3, and PI3K signaling pathways, enhances resistance 
to apoptosis mediated by Fas/Fas ligand interactions or by cyto-
kine withdrawal, and it can allow macrophages to better survive 
under the inflammatory conditions of the RA synovium (12–14). As 
changes in the number of synovial macrophages and the expres-
sion of inflammatory products reflect therapeutic efficacy (15, 
16), the strategy of incapacitating or reducing the synovial macro-
phage population may be effective for the treatment of RA. How-
ever, an unbiased and systematic approach has not been undertak-
en to determine the molecular signatures and biological networks 
of RA macrophages that underlie the roles of these macrophages 
in RA pathogenesis. In addition, the role of NFAT5 in the survival 
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which were ranked on the basis of their P values. Surprisingly, 
NFAT5 showed a more significant overlap between its regulon and 
DEGs in RA-SF macrophages than did TP53 and NF-κB complex-
es, suggesting that NFAT5 may be at least as significant as TP53 
and NF-κB in regulating RA macrophage pathology.
To predict the pathologic significance of NFAT5 as a key TF in 
RA-SF macrophages, we compared the 1,913 DEGs in RA-SF mac-
rophages with previously published data on RA patients’ synovial 
fibroblasts (RA-FLS) and HUVECs perturbed by NFAT5 down-
regulation via siRNA (22). Among the 1,493 NFAT5 target genes 
identified in RA-FLS and HUVECs, 302 DEGs overlapped with the 
1,913 DEGs found in RA-SF macrophages (P < 0.00001) (Figure 
1C). We further analyzed cellular processes enriched by the DEGs 
in RA-SF macrophages. Functional enrichment analysis revealed 
that leukocyte proliferation, cell-cycle regulation, apoptosis, cell 
death, actin cytoskeletal organization, and response to ROS were 
significantly enriched (P < 0.01) by the 1,015 DEGs upregulated in 
RA-SF macrophages (Figure 1D). Interestingly, the DEGs involved 
in the cell-cycle regulation, apoptosis, cell death, and proliferation 
overlapped with more than 25% of the NFAT5 target genes (blue 
bars in Figure 1D), suggesting that these are predominant cellular 
processes represented by the DEGs in RA macrophages and that 
NFAT5 controls the survival and proliferation of macrophages in 
patients with RA.
Indeed, NFAT5 expression was higher in RA-SF macro-
phages than in normal macrophages differentiated from periph-
eral CD14+ cells, as determined by quantitative real-time PCR 
(qRT-PCR), Western blotting, and flow cytometry (Figure 1E). 
We sought to determine which factors contribute to the enhanced 
NFAT5 expression in RA-SF macrophages. RA-SF macrophages 
are exposed to a number of proinflammatory cytokines, growth 
factors, and hypoxia (6). As shown in Figure 2A, macrophage-CSF 
(M-CSF), IL-1β, and the CoCl2 hypoxic stimulus increased NFAT5 
expression in peripheral CD14+ cells isolated from mononuclear 
cells of healthy controls. The M-CSF–induced increase in NFAT5 
expression was related to the differentiation of monocytes into 
the M1 macrophage subset, since M1-polarizing stimuli (IFN-γ 
plus LPS), but not the M2-polarizing cytokine IL-4, synergistical-
ly increased NFAT5 expression in M-CSF–stimulated CD14+ cells 
(Figure 2B). Moreover, NFAT5 expression in RA macrophages 
also increased in response to the hypoxic stimulus CoCl2, hypoxia 
chamber treatment (O2 <1%), or TLR4 ligation with LPS as deter-
mined by Western blotting and flow cytometry (Figure 2, C and 
D). Together, these data suggest that the proinflammatory cyto-
kine IL-1β and M1-polarizing stimuli are responsible for NFAT5 
upregulation in the course of differentiation of monocytes into 
macrophages in inflamed RA joints and that after differentiation, 
hypoxic conditions can further increase NFAT5 expression in acti-
vated macrophages.
NFAT5-regulated transcriptomes in macrophages. Given the 
microarray data analysis of RA macrophages (Figure 1, A–D), we 
wanted to test whether NFAT5 is essential for macrophage sur-
vival, apoptosis, and proliferation. To this end and for a better 
understanding of the role for NFAT5 in macrophage biology, we 
performed transcriptomic analysis of RAW 264.7 macrophages 
stably deficient in NFAT5 expression. To identify more reliable 
NFAT5 transcriptional targets, we used 2 strategies: a) stable 
of RA macrophages has not yet been documented, even though 
it is known that NFAT5 supports the expression of a group of key 
proinflammatory genes (2, 5, 17).
A number of innate and adaptive immune cells interact via 
an array of cytokines and/or cell-to-cell contacts, generating a 
complex inflammatory network within the RA synovia (6, 18). 
This complexity presents challenges when trying to determine 
the specific roles of synovial macrophages in the progression of 
RA. Comparative and unbiased analyses of gene expression pro-
files in a single cell population freshly isolated from pathological 
sites may help to identify the predominant signatures of a certain 
type of cells involved in RA pathogenesis (19). Here, we performed 
global transcriptomic profiling of synovial macrophages isolated 
from RA patients and of NFAT5-deficient macrophages. Analysis 
of the transcriptomes in the 2 types of macrophages revealed that 
NFAT5 was a central regulator for diverse pathological processes 
of RA macrophages, including the cell cycle, apoptosis, and pro-
liferation. Very interestingly, NFAT5 showed a more significant 
overlap between its regulon and differentially expressed genes 
(DEGs) in RA synovial macrophages than did TP53 and NF-κB 
complexes. Proinflammatory M1-polarizing stimuli and hypoxic 
conditions were responsible for enhanced NFAT5 expression in 
RA macrophages. Functional studies in vitro demonstrated that 
NFAT5 promoted survival and prevented apoptosis by inducing 
CCL2 production in both human and murine macrophages. More-
over, in mice, NFAT5-deficient macrophages were less efficient 
in promoting joint damage than were NFAT5-sufficient macro-
phages when injected intra-articularly. Taken together, it can be 
suggested that NFAT5 regulates macrophage survival and thereby 
plays a major role in the progression of RA.
Results
Transcriptomic analysis of RA macrophages reveals NFAT5 to be a 
key TF. One of the most recognized features of RA is an increased 
number of synovial macrophages in the intimal and subintimal 
compartments (8) and that the number of these synovial mac-
rophages correlates with RA activity and severity (10, 11). Also, 
macrophage depletion brings a resolution of chronic arthritis in 
both mouse and human systems (20, 21). However, a systematic 
analysis of the TFs or regulators as possible drivers of RA macro-
phage pathology has not been done. To address this, we first pro-
filed the global expression of genes in synovial fluid macrophages 
from RA patients (RA-SF macrophages) and normal macrophages 
differentiated from peripheral CD14+ monocytes using the Illumi-
na HumanRef-8 v3.0 microarray. As a result, we identified 1,913 
DEGs comprising 1,015 upregulated and 898 downregulated 
genes with an FDR of less than 0.05 and a fold change of greater 
than 1.5 between RA-SF macrophages and normal macrophages 
using an integrative statistical method (Figure 1A). Subsequently, 
we investigated key TFs responsible for DEGs in RA-SF macro-
phages using a master regulator analysis algorithm (see Methods 
and Supplemental Methods). The algorithm computed the statis-
tical significance of the overlap between the regulon of each TF 
and the DEGs in RA-SF macrophages. Among the 259 TFs, we 
identified 19 key TFs that had a P value of less than 0.05. Figure 
1B shows the top 10 TFs including SP1, SPI1, NFAT5, NF-κB com-
plexes (REL, RELB, RELA, and NFKB2), PPARG, TP53, and E2F4, 
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eration, DNA repair, RNA processing, mitochondrial processes, 
epigenetic regulation, transport, cell death, and ER stress (Figure 
3C). Of note, cell proliferation and cell death were two of the most 
significant biologic processes functionally enriched by the DEGs, 
as determined by their enrichment scores (Figure 3C), suggesting 
that these are the predominant cellular processes regulated by 
NFAT5 in macrophages.
We focused on macrophage survival and proliferation as the 
major biological processes regulated by NFAT5. Biological networks 
delineating key cellular processes are essential to understanding the 
function of a gene at the molecular level (19). Thus, we integrated 
NFAT5-dependent modules involving DNA repair, cell-cycle regu-
lation, survival, death, and proliferation and then reconstructed a 
molecular network representing these processes (Figure 3D). Next, 
we selected 10 representative genes from NFAT5-regulated DEGs 
knockdown (NFAT5 KD) of Nfat5 transcripts in RAW 264.7 cells 
using shRNA for Nfat5; and b) a decoy system (NFAT5 decoy) that 
inhibits NFAT5 binding to its promoter by stable transduction of 
the cells with oligonucleotides harboring the consensus sequence 
for NFAT5 target genes (23). By an integrative statistical method, 
we identified 2,205 and 2,014 DEGs in RAW 264.7 macrophages 
with NFAT5 KD and NFAT5 decoy, respectively (Figure 3A). Com-
parison of the DEGs showed that 87% of the genes were in com-
mon to both NFAT5-KD and NFAT5 decoy cells, indicating that 
our approach to repressing transcriptional activity of NFAT5 was 
reliable. We then selected 1,893 of the 1,958 genes that were reg-
ulated in the same direction (up- or downregulated) as transcrip-
tional targets of NFAT5 in both conditions (Figure 3B). Cellular 
processes represented by the 1,893 genes were then categorized 
into 9 functional modules, which included translation, cell prolif-
Figure 1. Enhanced NFAT5 signature in RA synovial macrophages. (A) Heatmap displaying the differential expression patterns of 1,913 DEGs in CD14+ 
macrophages from RA-SF (n = 6) compared with normal macrophages (n = 2) differentiated from peripheral CD14+ monocytes. Red and green colors denote 
upregulation and downregulation, respectively. Mφ, macrophages. (B) Top 10 TFs enriched by up- and downregulated DEGs in RA synovial macrophages. 
(C) Venn diagram depicting the overlap between DEGs in synovial macrophages from RA patients and those in NFAT5-deficient RA synovial fibroblasts 
and human endothelial cells. P value indicates the significance of 302 overlapping DEGs, including 176 upregulated and 126 downregulated DEGs. Empirical 
hypothesis testing based on 100,000 random permutations was performed to determine the P value of the overlapping DEGs. (D) Cellular processes 
enriched by the DEGs in synovial macrophages from RA patients. Heatmap with violet color gradient represents the level of significance for each cellular 
process. Dark violet and bright violet refer to high (P < 0.01) and moderate (P < 0.05) enrichment, respectivel. The P values were determined by DAVID soft-
ware using a hypergeometric test method. The bar graph on the right depicts the percentages of overlap between the DEGs associated with each cellular 
process and NFAT5 target genes. (E) Enhanced NFAT5 expression in RA synovial macrophages. Synovial macrophages were freshly isolated from synovial 
fluid of RA patients using anti-CD14 magnetic beads. Normal macrophages were differentiated from peripheral monocytes of healthy subjects. NFAT5 
expression was determined by real-time PCR (n = 9), Western blot, and flow cytometric analyses. The gray plot in the flow cytometric graph indicates the 
isotype control in normal macrophages. NFAT5 mRNA expression is shown as a the fold increase relative to GAPDH mRNA. Data represent the mean ± SD. 
**P < 0.005 versus normal macrophages, by Mann-Whitney U test.
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pared with the control cells. The frequency of annexin V+ and/or 
PI+ cells induced by thapsigargin (TG) and sodium nitroprusside 
(SNP) was also higher in NFAT5-KD RAW 264.7 macrophages 
than in control vector–transfected cells (Figure 4B), indicating 
that NFAT5 deficiency renders RAW 264.7 macrophages more 
susceptible to TG- or SNP-induced apoptosis. In parallel, when 
treated with SNP, NFAT5-KD RAW 264.7 macrophages showed 
a decrease in antiapoptotic BCL-2 expression and an increase 
in proapoptotic caspase 8 expression compared with expres-
sion levels seen in controls cells (Supplemental Figure 1A). The 
starvation-, CHX-, or TG-induced increase in cleaved caspase 8 
expression was also greater in NFAT5-KD cells than in control 
cells (Supplemental Figure 1, B–D). Moreover, cell viability, as 
determined by MTT assay, was significantly lower in NFAT5-de-
ficient RAW 264.7 macrophages (in both NFAT5-KD and NFAT5 
decoy cells) in the presence of CHX, SNP, or TG than in control 
cells (Figure 4C), indicating that NFAT5 controls the survival of 
RAW 264.7 macrophages and that, with reduced NFAT5 activity, 
they are more susceptible to apoptosis.
Compared with control cells, the number of viable cells assessed 
by trypan blue exclusion was significantly reduced for NFAT5-defi-
cient RAW 264.7 macrophages, with a reduction of approximately 
25% to 30% over a 96-hour culture period (Figure 4D). The prolifer-
and validated their differential expression using qRT-PCR. As 
shown in Figure 3E and Supplemental Table 1 (supplemental mate-
rial available online with this article; doi:10.1172/JCI87880DS1), 
the expression levels of Cd74, Sod2, Ccl2, Bop1, Cdkn2d, and Ran 
mRNA, which are involved in cell-cycle regulation, survival, and 
proliferation (24–28), were decreased in NFAT5-deficient RAW 
264.7 cells when compared with levels in control vector–transfected 
cells. In contrast, the expression levels of Dap3, Fas, Stk3, and Tiam1 
mRNA, which promote apoptotic death (13, 29–31), were increased 
in the same cells. Moreover, the same relative changes in RNA mes-
sage levels were observed in NFAT5-deficient (via shRNA) CD14+ 
macrophages from human subjects as those in NFAT5-deficient 
RAW 264.7 cells (Figure 3E and Supplemental Table 1). Collective-
ly, these data support the view that NFAT5 may control the survival 
and proliferation of macrophages.
NFAT5 is required for macrophage survival and proliferation. To 
verify the hypothesis on NFAT5 regulation of macrophage sur-
vival and proliferation, we performed flow cytometric analysis 
and an MTT (tetrazolium) assay of NFAT5-deficient RAW 264.7 
macrophages. As shown in Figure 4A, NFAT5-KD RAW 264.7 
macrophages treated with cycloheximide (CHX) for 24 hours 
showed an increase in the frequency of FITC–annexin V+ and/or 
propidium iodide+ (PI+) cells on flow cytometric analysis as com-
Figure 2. Induction of NFAT5 expression in macrophages by M1 polarizing and hypoxic stimuli. (A) Increase in NFAT5 expression by IL-1β, M-CSF, and CoCl2. 
Peripheral blood CD14+ cells from healthy controls were stimulated with M-CSF (20 ng/ml), IL-1β (10 ng/ml), or TNF-α (10 ng/ml) for 48 hours. CoCl2 was 
treated again for 6 hours after stimulation with M-CSF. NFAT5 expression was determined by Western blot and flow cytometric analyses. Data represent the 
mean ± SD and are representative of 3 independent experiments. *P < 0.05 versus media only, by Mann-Whitney U test. (B) Increase in NFAT5 expression 
by M1-polarizing stimuli. Normal peripheral monocytes (CD14+ cells) were stimulated with M-CSF (20 ng/ml) for 48 hours and then stimulated again with 
IL-4 (20 ng/ml) or IFN-γ (20 ng/ml) plus LPS (100 ng/ml). NFAT5 expression was determined by Western blot analysis. Data represent the mean ± SD of 3 
independent experiments. *P < 0.05 versus M-CSF only, by Mann-Whitney U test. (C and D) Hypoxia-induced increase in NFAT5 expression in RA synovial 
macrophages. CD14+ macrophages were freshly isolated from RA-SF and stimulated with CoCl2 or in the hypoxia chamber (O2 <1%). NFAT5 expression was 
determined by Western blot analysis (C) after 24 hours and flow cytometric analysis (D) after 6 hours. Data are representative of 3 separate experiments.
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Figure 3. Molecular targets of NFAT5 involving RAW 264.7 macrophage survival and proliferation. (A–C) 
Comparative analysis of the transcriptomes in RAW 264.7 macrophages with NFAT5 shRNA (n = 3), control 
shRNA (n = 3), and NFAT5 decoy oligonucleotides (n = 3). Global gene expressions profiles were determined 
using the Illumina MouseWG-6 v2.0 array platform. (A) Venn diagram illustrates the overlap between DEGs 
in macrophages stably transfected with NFAT5 shRNA (NFAT5 KD) and those transduced stably with NFAT5 
decoy oligonucleotides (TGGAAAATTACCG, NFAT5 decoy). (B) Heatmap showing differential expression 
patterns of 2,261 DEGs in NFAT5 KD and the NFAT5 decoy compared with the corresponding controls. (C) 
Cellular processes enriched by 1,074 (Down) and 819 (Up) DEGs in the same direction between NFAT5 KD and 
the NFAT5 decoy. Significantly enriched processes for common DEGs were scored with respect to the P value 
obtained. Selected processes were grouped into 9 functional classes on the basis of the similarity of gene 
ontology terms defined by the kappa score. The color gradient on the right represents the enrichment score 
defined as –log10 (P value). Enrichment scores are displayed in a violet color gradient: dark violet (P < 0.01), 
bright violet (P < 0.05), and white (P > 0.05). The significance of the enrichment was determined using a 
hypergeometric test. (D) Network model describing the functional modules, which are functionally aggregated 
with the DEGs associated with cell proliferation, apoptosis, and survival. Node color represents upregulated 
(red) and downregulated (turquoise) gene expression in NFAT5 KD and the NFAT5 decoy compared with con-
trol. Gray lines indicate interactions between 2 genes. Expression levels of the genes marked with an asterisk 
were confirmed by real-time PCR in Figure 3E. (E) mRNA expression levels of representative NFAT5-regulated 
genes involved in cell survival, proliferation, and apoptosis in NFAT5 KD RAW 264.7 macrophages (upper pan-
el) and NFAT5 shRNA–transfected human macrophages (lower panel), as determined by real-time PCR. Data 
represent the mean ± SD of 3 independent experiments performed in duplicate.
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ation of RAW 264.7 macrophages was decreased in the NFAT5-KD 
or the NFAT5 decoy cells, as determined by a BrdU incorporation 
assay (Figure 4E), suggesting that NFAT5 deficiency reduced the 
proliferation of RAW 264.7 macrophages.
To demonstrate whether primary macrophages are controlled 
by NFAT5 in a manner similar to that seen with RAW 264.7 mac-
rophages, we investigated the effect of NFAT5 deficiency on the 
apoptosis and survival of murine peritoneal macrophages. Since 
complete NFAT5 deficiency is developmentally lethal, we used 
a line of mice heterozygous for NFAT5 [referred to hereafter as 
Nfat5+/– mice] with an inactive allele (32). The heterozygotes dis-
played haploinsufficiency of Nfat5 mRNA and protein expression 
in many tissues and cells, including macrophages (data not shown 
and ref. 32). As expected, apoptotic cell death induced by CHX, 
SNP, or TG, as assessed by follow cytometry, was substantially 
higher in Nfat5+/– macrophages than in WT (Nfat5+/+)macrophages 
Figure 4. NFAT5 regulates the survival and proliferation of RAW 264.7 macrophages. (A) Increased apoptotic death in NFAT5-deficient RAW 264.7 
macrophages. The degree of apoptosis was assessed in NFAT5 shRNA–transfected (NFAT5 KD) RAW 264.7 macrophages versus control vector–transfected 
cells (Control) 24 hours after treatment with CHX (0.5 μg/ml), TG (100 nM), or SNP (100 μM) using flow cytometry for FITC–annexin V and PI. Data are rep-
resentative of 3 independent experiments. (B and C) Decreased viability of NFAT5-deficient RAW 264.7 macrophages. NFAT5 KD RAW 264.7 macrophages 
(1 × 105 cells) were treated with CHX (0–4 μg/ml), SNP (0–1,200 μM), or TG (0–500 nM) for 24 hours. RAW 264.7 macrophages stably transduced with the 
NFAT5 decoy were treated with CHX (0.5 μg/ml), SNP (1.2 mM), or TG (16 nM) for 24 hours. Cell viability was determined by MTT assay. Data represent the 
mean ± SD of 3 independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 versus control vector–transfected RAW 264.7 cells, by 1-way ANOVA 
with Tukey’s post-hoc test. (D and E) Reduction of RAW 264.7 cell proliferation due to NFAT5 deficiency. RAW 264.7 macrophages (1 × 104 cells) stably 
transfected with NFAT5 shRNA (NFAT5 KD) or stably transduced with NFAT5 decoy were cultured for 96 hours in RPMI 1640 containing 10% FBS. Viable 
cells were manually counted after trypan blue staining (D). Cell proliferation was determined by BrdU assay following a 12- or 24-hour incubation with 10% 
FBS (E). Data represent the mean ± SD. *P < 0.05 and **P < 0.001 versus control vector–transfected cells, by 1-way ANOVA with Tukey’s post-hoc test.
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(Supplemental Figure 2). Moreover, the mean annexin V fluores-
cence intensity was significantly higher in splenic macrophages 
from Nfat5+/– mice than in those from Nfat5+/+ mice, as determined 
6 days after incubation (Figure 5A). The extent of apoptotic death 
induced by the CoCl2 hypoxic stimulus was also higher in splenic 
Nfat5+/– macrophages (Figure 5B), confirming that NFAT5 insuf-
ficiency promotes apoptosis of primary macrophages. In parallel, 
macrophage survival under serum-free (starvation) conditions 
was significantly lower in Nfat5+/– macrophages than in Nfat5+/+ 
macrophages, as measured by MTT assay (Figure 5C). Addition-
ally, the number of cells stimulated with 10% FBS for 48 hours 
was significantly reduced in Nfat5+/– macrophages (Figure 5D). 
The extent of BrdU incorporation was also lower in Nfat5+/– mac-
rophages than in Nfat5+/+ macrophages (Figure 5E), which sug-
gests that NFAT5 is involved in the proliferation of primary mouse 
macrophages. Moreover, the NFAT5-mediated deficiency in mac-
rophage survival and proliferation was reproduced in bone mar-
row–derived macrophages (BMDMs) isolated from Nfat5+/– mice 
(Supplemental Figure 3). Taken together, these results demon-
strate that NFAT5 is required for the survival and proliferation of 
RAW 264.7 and primary macrophages.
The NFAT5 target CCL2 is necessary for RA macrophage sur-
vival. We performed our next experiment to validate whether 
NFAT5 actually controls the survival of RA macrophages and, if 
so, to determine which target genes of NFAT5 are predominantly 
involved in this process. To this end, we first performed qRT-PCR 
analysis for the representative NFAT5-regulated genes shown in 
Figure 3E in independent RA-SF macrophage samples. In sharp 
contrast to NFAT5-deficient conditions, CD74, SOD2, and CCL2 
mRNA expression was increased in RA-SF macrophages, whereas 
APAF1, DAP3, STK3, and FAS mRNA expression was decreased in 
the same cells (Figure 6A). In particular, CCL2 was the most highly 
expressed gene among the 10 NFAT5 target genes in RA-SF mac-
rophages (Figure 6A), with a 76.3-fold higher mean level of CCL2 
mRNA detected in RA macrophages than in normal macrophages.
CCL2 promotes the survival of human CD11b+ peripher-
al blood mononuclear cells (PBMCs) (24). To predict the role of 
CCL2 in the survival of RA macrophages, we reconstructed a 
CCL2-centered network using the DEGs in RA-SF macrophages. 
Supplemental Figure 4A and Supplemental Table 2 illustrate sig-
nificant interactions among the first neighbors of CCL2 that are 
associated with cell proliferation, survival, and antiapoptosis 
(P < 0.00001), which suggests a CCL2-dependent regulation of 
RA macrophage survival. In support of this observation, expres-
sion of CD44 and OLR1, the first neighbors of CCL2, was signifi-
cantly higher in CCL2+ macrophages than in CCL2– macrophages 
in RA-SF, as determined by flow cytometry (Supplemental Figure 
4B). Thus, we postulated that CCL2 is secreted by RA macro-
phages in an NFAT5-dependent manner and contributes to RA 
macrophage survival in an autocrine and paracrine manner.
Figure 5. Decrease in survival and proliferation of primary mouse macrophages due to NFAT5 deficiency. (A and B) Increased apoptosis in primary macro-
phages due to NFAT5 haploinsufficiency. Splenic macrophages (2 × 105 cells) from WT Nfat5+/+ and Nfat5+/– mice were obtained 24 hours after i.p. injection 
of LPS (10 mg/kg) and were cultured in RPMI containing 10% FBS for 4 and 6 days (A) or in the presence of CoCl2 (100 μM) for 2 days (B). The extent of 
apoptotic death was determined by flow cytometry for annexin V and by MTT assay. *P < 0.05 versus WT Nfat5+/+ macrophages, by Mann-Whitney U test. 
(C) Starvation-induced cell death in Nfat5+/+ versus Nfat5+/– mice, as determined by MTT assay. *P < 0.05 versus Nfat5+/+ macrophages, by Mann-Whitney U 
test. (D and E) Decreased proliferation of primary macrophages due to NFAT5 insufficiency. Thioglycollate peritoneal macrophages (1 × 105 cells) fromNfat5+/+ 
and Nfat5+/– mice were stimulated with RPMI 1640 containing 10% FBS. Cell proliferation was determined by MTT assay (D) or BrdU assay (E) after a 24- and 
48-hour incubation. *P < 0.05 versus Nfat5+/+ macrophages, by Mann-Whitney U test. Data in B–E were compiled from 2 experiments (n = 4 mice per group).
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in CCL2 secretion by normal macrophages (Figure 6E); a reduc-
tion of CCL2 secretion was also seen in NFAT5-deficient RAW 
264.7 macrophages (Supplemental Figure 6A). Collectively, these 
observations suggest that CCL2 is produced by RA macrophages 
via an NFAT5-dependent pathway upon TLR4 ligation and proin-
flammatory cytokine stimulation. To investigate whether NFAT5 
promotes RA macrophage survival via CCL2 secretion, we per-
formed annexin V staining of RA-SF macrophages in the presence 
of exogenous CCL2 after transfection of NFAT5 shRNA using a 
lentiviral system. As shown in Figure 6F, NFAT5 shRNA signifi-
cantly increased the mean intensity of annexin V+ cells as com-
pared with control (scrambled) shRNA, which was completely 
recovered by the addition of recombinant CCL2.
To explore this hypothesis, we first determined CCL2 expres-
sion levels in human monocytes stimulated with proinflamma-
tory cytokines and LPS. As reported previously (2, 22), we found 
that NFAT5-inducing stimuli, including M-CSF, IL-1β, and LPS, 
could upregulate the expression of CCL2 in normal peripheral 
CD14+ cells as determined by ELISA and flow cytometry (Figure 
6, B and C). Interestingly, CCL2+ RA macrophages had higher 
levels of NFAT5 than did CCL2– RA macrophages (Figure 6D). 
Double immunofluorescence staining of RA synovium also 
revealed the coexpression of NFAT5 and CCL2 in CD14+ macro-
phages, however, NFAT5– macrophages only weakly expressed 
CCL2 (Supplemental Figure 5). Moreover, NFAF5 KD with 
sh RNAs using a lentiviral system resulted in a significant decrease 
Figure 6. The NFAT5 target CCL2 prevents apoptotic death of RA macrophages. (A) mRNA expression levels of representative NFAT5-regulated genes 
involved in cell survival, proliferation, and apoptosis in RA-SF macrophages (n = 8) compared with normal macrophages (n = 8), as determined by real-time 
PCR and presented according to fold change. (B and C) Increased CCL2 expression in CD14+ cells in response to NFAT5-inducing stimuli. Peripheral blood 
CD14+ cells (1 × 106 cells) from healthy controls (n = 6) were stimulated with M-CSF (20 ng/ml), IL-1β (10 ng/ml), and LPS (100 ng/ml) for 12 hours (B) or 24 
hours (C). CCL2 expression in the culture supernatants was determined by ELISA (B) and intracellular flow cytometry (C). (D) NFAT5 expression in CCL2+ 
versus CCL2– subpopulations of RA-SF macrophages (n = 3), as determined by flow cytometry. Gates for the CCL2+ or CCL2– cells are shown in the flow cyto-
metric dot plot. Histogram shows the difference in NFAT5 expression according to CCL2 positivity. MFI, mean fluorescence intensity. (E) Decreased CCL2 
secretion by NFAT5-deficient human macrophages. Peripheral CD14+ cells (1 × 106 cells, n = 4) were stimulated with M-CSF for 24 hours and then transfect-
ed with NFAT5 shRNA or control shRNA for a further 24 hours. CCL2 levels in the culture supernatants were measured by ELISA (bar graph) and were also 
assessed by flow cytometry (flow cytometric dot plot) in macrophages 24 hours after stimulation with 10 ng/ml LPS. (F) Effect of CCL2 on NFAT5-depen-
dent apoptosis of RA-SF macrophages. RA-SF macrophages (2 × 105 cells) were transfected with NFAT5 shRNA or control shRNA for 24 hours. The cells 
were then cultured in the presence or absence of 100 ng/ml recombinant CCL2 (rCCL2) (n = 5) for 24 hours. The extent of apoptosis was determined by flow 
cytometry for annexin V. Bar graphs in A–F represent the mean ± SD. (A) *P < 0.05 and **P < 0.001 versus normal macrophages, by Mann-Whitney U test. 
(B and C) **P < 0.001 versus media only, by 1-way ANOVA with Tukey’s post-hoc test. (D, E, and F) *P < 0.05 between groups, by Mann-Whitney U test. 
FSC, forward scatter; SSC, side scatter.
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RA peripheral monocytes show increased survival but decreased 
apoptotic death. Monocytes derived from progenitors in bone mar-
row are an important source of synovial-resident macrophages 
(33), and recent evidence suggests that self-renewal macrophages 
give rise to another origin of many tissue-resident macrophages 
(33). It is believed, however, that resident macrophages do not 
recirculate into the periphery. Since RA is a systemic disease, we 
wondered a) whether RA peripheral monocytes show increased 
survival but decreased apoptotic death, like RA-SF macrophages 
and b) whether they reflect RA-SF macrophages when cell sur-
vival and proliferation as well as NFAT5 and CCL2 expression 
are simultaneously assessed in peripheral monocytes and syno-
vial macrophages of RA patients. We found that expression levels 
of both NFAT5 and CCL2 were significantly higher in matched 
RA-SF CD14+ cells than in peripheral CD14+ cells, which were 
collected at the same time (Figure 8A and Supplemental Figure 
6B). Very interestingly, NFAT5 expression in matched synovial 
CD14+ cells correlated well with that detected in simultaneously 
obtained peripheral monocytes (Figure 8B), thus suggesting that 
To exclude the off-target effects of shRNA on NFAT5, we 
used primary macrophages from Nfat5+/– mice. We isolated mac-
rophages from splenic cells activated with LPS in vivo or from 
peritoneal cells stimulated with thioglycollate in vivo and tested 
whether NFAT5 regulates macrophage survival via CCL2. When 
stimulated with LPS for 24 hours, Nfat5+/– macrophages produced 
significantly lower levels of CCL2 than did WT Nfat5+/+ macro-
phages (Figure 7A). Next, thioglycollate-peritoneal macrophages 
or splenic F4/80+ macrophages from Nfat5+/+ mice were exposed 
to anti-CCL2–neutralizing Ab, and their cell viability was exam-
ined. The results showed that macrophages (peritoneal and splen-
ic) treated with anti-CCL2–neutralizing Ab displayed an increase 
in apoptosis (Figure 7B) and a decrease in cell viability (Figure 7C) 
as compared with vehicle-treated cells. Conversely, the addition 
of recombinant CCL2 restored apoptosis of Nfat5+/– splenic mac-
rophages (Figure 7D), while the same concentration of recombi-
nant IL-6 or TNF-α failed to do so (data not shown). Taken togeth-
er, these data suggest that NFAT5 promotes macrophage survival 
by inducing CCL2 production in human and murine systems.
Figure 7. NFAT5 promotes the survival of primary mouse macrophages by inducing CCL2 secretion. (A) CCL2 secretion by macrophages from WT 
Nfat5+/+ and Nfat5+/– mice. Peritoneal macrophages (1 × 105 cells) were isolated 96 hours after i.p. injection of thioglycollate and then stimulated with 
LPS (100 ng/ml) for 24 hours. CCL2 concentrations in the culture supernatants were measured by ELISA. Data were compiled from 2 experiments (n = 4 
mice per group) and are presented as the mean ± SD. *P < 0.05, by Mann-Whitney U test. (B) Increased apoptosis of splenic macrophages in response 
to anti-CCL2 Ab. Splenic macrophages (2 × 105 cells) from Nfat5+/+ mice were treated with anti-CCL2–neutralizing Ab (5 μg/ml) for 48 hours. The degree 
of apoptosis was determined by flow cytometry for annexin V. Data represent the mean ± SD of 3 independent experiments (n = 6 per group). *P < 0.05, 
by Mann-Whitney U test. (C) Reduced proliferation of thioglycollate macrophages in response to anti-CCL2 Ab. Thioglycollate peritoneal macrophages 
(1 × 105 cells) from Nfat5+/+ mice were stimulated with 10% FBS for 48 hours in the presence or absence of anti-CCL2 Ab (5 μg/ml). Cell viability was 
assessed by MTT assay. Data represent the mean ± SD of 3 independent experiments (n = 6 per group). *P < 0.05 between groups at each time point, by 
Mann-Whitney U test. (D) CCL2 restored apoptosis of Nfat5+/– macrophages. Splenic F4/80+ macrophages (2 × 105 cells) from Nfat5+/– mice were treated 
with recombinant CCL2 (200 ng/ml) for 6 days. Apoptosis was assessed by flow cytometry for annexin V. Data were compiled from 2 experiments (n = 4 
mice per group). *P < 0.05, by Mann-Whitney U test.
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of peripheral CD14+ cells was significantly higher in RA patients 
than in healthy controls (Figure 8E). Moreover, peripheral mono-
cytes from patients with RA showed a lesser degree of apoptotic 
death than did those from healthy controls when cultured for 96 
hours (Figure 8, F and G). Basal levels of apoptosis also were sig-
nificantly lower in peripheral CD14+ monocytes from RA patients 
than in those from healthy controls (Figure 8H). Similar to the data 
NFAT5 positivity in RA-SF macrophages, in part, comes from 
the peripheral NFAT5hi monocytes. In addition, the frequency of 
CD14+ cells in PBMCs correlated well with that of paired synovial 
fluid mononuclear cells (SFMCs) in patients with RA (Figure 8C), 
and the mean level of CD14+ cells was 2-fold higher in RA patients 
than in healthy controls (Figure 8D). In parallel, when cultured 
in RPMI 1640 media with 10% FBS for 96 hours, the frequency 
Figure 8. Peripheral CD14+ cells from RA patients are resistant to apoptotic death. (A and B) Comparison of NFAT5 expression levels in CD14+ cells between 
PBMCs and SFMCs from patients with RA (n = 6) (cells were obtained simultaneously). (C) Correlation of CD14+ cell frequencies between paired SFMCs and 
PBMCs from patients with RA, as assessed by flow cytometry. (D) Increase in the proportion of CD14+ cells in PBMCs from patients with RA. The percentages 
of CD14+ cells in PBMCs from RA patients (n = 14) and healthy controls (n = 12) were assessed by flow cytometry. (E) Time kinetics for the frequency of CD14+ 
cells in PBMCs from RA patients (n = 5) versus normal controls (n = 4). PBMCs were cultured for 96 hours in RPMI 1640 containing 10% FBS. The proportion 
of CD14+ cells in PBMCs was determined by flow cytometry. (F) Increased viability of peripheral CD14+ cells from patients with RA. CD14+ cells (5 × 105 cells), 
isolated from PBMCs from RA patients (n = 7) and healthy controls (n = 6), were cultured for 96 hours in RPMI 1640 containing 10% FBS. Cell viability was 
determined by MTT assay. (G) Time kinetics of apoptosis in CD14+ cells from RA patients (n = 6) versus healthy controls (n = 6). CD14 cells (5 × 105 cells) were 
cultured for 96 hours in RPMI 1640 containing 10% FBS. Cell apoptosis was determined by flow cytometry for annexin V. (H) Decrease in the proportion of 
apoptotic CD14+ cells in PBMCs from patients with RA. Mononuclear cells were isolated from the peripheral blood of RA patients (n = 11) and healthy controls 
(n = 11). The proportion of annexin V+ cells in CD14+ cells was assessed by flow cytometry immediately after isolating the PBMCs. (I) A positive correlation 
between NFAT5 and CCL2 mRNA levels was found in CD14+ cells from patients with RA. Data in A and D–H represent the mean ± SD. (A and D–H) *P < 0.05, 
by Mann-Whitney U test. (B, C, and I) Statistical significance was determined by Spearman’s correlation analysis.
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NFAT5-deficient mice is dependent on CCL2. As expected, CCL2 
expression was significantly lower in the joints of Nfat5+/– mice 
than in those of Nfat5+/+ mice (Figure 9C). When recombinant 
CCL2 was injected repeatedly into one of the affected joints of 
Nfat5+/– mice with IL-1β–induced arthritis, we found that macro-
phage infiltration was significantly increased as compared with 
that in vehicle-treated mice (Figure 9D, left and middle panels). 
Moreover, the extent of inflammation and joint destruction was 
more severe in mice injected with CCL2 (Figure 9D, right panel), 
which confirms the essential role of the NFAT5/CCL2 axis in mac-
rophage infiltration and arthritis progression in vivo.
Finally, we tested the direct role of NFAT5-sufficient mac-
rophages in promoting arthritis severity. When splenic macro-
phages from WT Nfat5+/+ mice were injected into the knee joints 
of Nfat5+/+ mice just prior to induction of mBSA/IL-1β–mediated 
arthritis, the histological severity assessed on day 7, including 
inflammatory cell infiltration, bone destruction, and synovial 
on synovial CD14+ cells (Figure 6D), NFAT5 mRNA expression in 
peripheral CD14+ cells correlated well CCL2 mRNA expression 
(Figure 8I). Collectively, these observations suggest that peripher-
al monocyte numbers are increased in patients with RA and show 
apoptotic resistance and increased survival, which might be asso-
ciated with increased expression of NFAT5.
NFAT5 in macrophages is essential for the progression of chronic 
arthritis in mice. To ascertain the effect of the NFAT5/CCL2 axis 
in macrophages on chronic arthritis, we next generated methylat-
ed BSA/IL-1β–induced (mBSA/IL-1β–induced) arthritis, a model 
of chronic arthritis in which macrophages play a central role (34), 
in Nfat5+/– mice and their WT littermates. As shown in Figure 9, A 
and B, inflammatory cell infiltration, including macrophage infil-
tration and synovial hyperplasia, was significantly lower in NFAT5 
haploinsufficient mice than in WT Nfat5+/+ mice, indicating that 
NFAT5 plays a key role in arthritis progression in this model. We 
next investigated whether the decrease in arthritis severity in 
Figure 9. In vivo role of the NFAT5/CCL2 axis in macrophage infiltration and arthritis progression. (A) Effect of NFAT5 haploinsufficiency on arthritis 
severity in mice with mBSA/IL-1β–induced arthritis. Joint sections from WT Nfat5+/+ and Nfat5+/– mice were stained with H&E, and arthritis severity was 
graded from 0 to 3 on day 7 (see the Supplemental Methods for additional details). The rectangular areas in the left panels are shown at higher magni-
fication in the right panels. Scale bar: 200 μm (left panels) and 100 μm (right panels). Bar graph shows the mean ± SD of the histological grade (n = 5 per 
group). **P < 0.001 between groups, by Mann-Whitney U test. (B) Reduced infiltration of macrophages from Nfat5+/– mice with mBSA/IL-1β–induced 
arthritis. Infiltrated macrophages were stained using a macrophage marker Ab (RM0029-11H3), and their numbers are expressed as the M score, which is 
the product of staining frequency (percentage) multiplied by the intensity. Bar graph shows the mean ± SD. Scale bars: 100 μm. *P < 0.01, by Mann-Whit-
ney U test. (C) Reduced CCL2 expression in the knee joints of Nfat5+/– mice with mBSA/IL-1β–induced arthritis. Expression levels were assessed by IHC 
using anti-CCL2 Ab (ab25124). The H score is the product of staining frequency (percentage) multiplied by the intensity and is presented as the mean ± SD 
(n = 5 per group). **P < 0.01, by Mann-Whitney U test. (D) Increase in arthritis severity by intra-articular injection of CCL2. Recombinant CCL2 (2 μg) was 
injected once daily on days 1, 3, and 5 into the knee joints of Nfat5+/– mice. The joint sections were stained with H&E and macrophage marker Ab on day 
7. Bar graphs show the mean ± SD (n = 5 per group). *P < 0.05 and **P < 0.01, by Mann-Whitney U test. Scale bars: 100 μm. BD, bone destruction; IFLM, 
inflammatory cell infiltration; SH, synovial hyperplasia.
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the knee joints of Nfat5+/– mice prior to the induction of mBSA/
IL-1β–mediated arthritis and investigated the effect of these mac-
rophages on arthritis severity. As shown in Figure 10C, on day 7, 
Nfat5+/– macrophages showed more caspase 3 positivity than did 
WT Nfat5+/+ macrophages. Moreover, inflammatory cell infiltra-
hyperplasia, was significantly increased (Figure 10, A and B), 
demonstrating a direct effect of NFAT5-sufficient macrophages 
on the progression of chronic arthritis. To confirm that NFAT5 
expression in macrophages is required for chronic arthritis, we 
injected Nfat5+/– macrophages or WT Nfat5+/+ macrophages into 
Figure 10. Direct in vivo effect of NFAT5 in macrophages on the progression of arthritis. (A and B) Increase in arthritis severity by intra-articular injection 
of NFAT5-sufficient macrophages. Activated macrophages (5 × 105 cells per mouse) stimulated with LPS (10 mg/kg) in vivo for 24 hours were isolated from 
the spleens of Nfat5+/+ mice and then injected intra-articularly into the knee joints of Nfat5+/+ mice prior to injection of mBSA/IL-1β. The joint sections were 
stained with safranin O and macrophage marker Ab on day 7 to assess histological severity (A) and the degree of macrophage infiltration (B), respectively. 
Bar graphs show the mean ± SD of the histological grades and M scores (n = 5 per group). The rectangular areas in A are shown at higher magnification in 
B. *P < 0.01 and **P < 0.001, by Mann-Whitney U test. Scale bars: 200 μm (A) and 100 μm (B). (C and D) Increased apoptosis of macrophages in vivo due to 
NFAT5 deficiency. Activated splenic macrophages (5 × 105 cells) from Nfat5+/+ and Nfat5+/– mice were injected into the knee joints of Nfat5+/– mice before the 
injection of mBSA/IL-1β (n = 6 per group). Arthritic joints were stained with macrophage marker Ab (left panel in C), anti–active caspase 3 Ab (right panel in 
C), or safranin O (D) on day 7. Active caspase 3 staining was performed on 4-μm tissue sections next to those stained with macrophage marker Ab from the 
same joint. Bar graphs show the mean ± SD of histological grades assessed by safranin O staining (for the safranin O score, see the Supplemental Methods) 
and apoptosis scores. The apoptosis score was calculated as the staining frequency (percentage) with anti–active caspase 3 Ab multiplied by the intensity. 
*P < 0.05 and **P < 0.005, by Mann-Whitney U test. Scale bars: 200 μm (C) and 100 μm (D).
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the proinflammatory and hypoxic stimuli, including M-CSF, 
IL-1β, LPS, and CoCl2, represented a distinct modality for NFAT5 
upregulation in macrophages. An emerging concept that defines 
the role of macrophages in RA is the notion of their high plasticity 
during development. M1 (classical, inflammatory) and M2 (alter-
native, antiinflammatory, tissue repair) represent two extremes of 
a spectrum of possible macrophage activation statuses (37). Here, 
M1-polarizing stimuli (IFN-γ plus LPS), but not an M2-polarizing 
stimulus (IL-4), further increased NFAT5 expression in M-CSF–
differentiated CD14+ cells. In the RA setting, it is thought that 
the most efficacious macrophage inhibition or depletion therapy 
will be the one that selectively targets proinflammatory M1 rath-
er than antiinflammatory M2 macrophages (38). Our data define, 
for the first time to our knowledge, the selective association of M1, 
but not M2, polarization with NFAT5 induction and suggest that 
proinflammatory M1-polarizing stimuli and hypoxic conditions 
are the major contributing factors in the enhancement of NFAT5 
expression in RA macrophages.
CCL2 is a classical inflammatory chemokine (39), and its expres-
sion is transcriptionally upregulated by PDGF, VEGF, and LPS (39). 
CCL2 is expressed by a variety of cell types, including leukocytes, 
smooth muscle cells, endothelial cells, fibroblasts, epithelial cells, 
and certain tumor cell lines (39). Recent studies have demonstrated 
that CCL2 promotes the survival of human CD11b+ PBMCs (24) and 
prostate cancer PC3 cells (40). Synovial macrophages are the domi-
nant source of CCL2 production (9), and CCL2 concentrations cor-
relate with IL-1β, IL-6, and IL-8 levels in RA-SF (9, 41).
Here, we demonstrated in the network model represented by 
the DEGs in RA-SF macrophages that CCL2 significantly inter-
acted with the first neighbors that are associated with cell prolif-
eration, survival, and antiapoptosis. As reported previously (4, 5), 
RAW 264.7 macrophages, primary mouse macrophages, and RA 
macrophages that were deficient in NFAT5 all showed a marked 
impairment in CCL2 production. In addition, CCL2 expression cor-
related well with NFAT5 expression in RA-SF macrophages and RA 
synovial tissues. Recombinant CCL2 almost completely restored 
apoptotic death of NFAT5-deficient macrophages in human and 
mouse systems; conversely, anti-CCL2–neutralizing Ab increased 
apoptosis of peritoneal and/or splenic macrophages in vitro. More-
over, when recombinant CCL2 was injected into one of the affect-
ed joints of Nfat5+/– mice, joint destruction as well as macrophage 
infiltration were substantially increased. Taken together, our work 
is the first to our knowledge to demonstrate that the NFAT5/CCL2 
axis is crucial to macrophage survival and suggests that CCL2 is 
secreted by RA macrophages in an NFAT5-dependent manner and 
contributes to RA pathology by conferring apoptotic resistance to 
synovial macrophages in an autocrine and paracrine manner. Not-
withstanding, since NFAT5 regulates a number of genes involved 
in RA macrophage apoptosis in addition to CCL2, including CD74, 
SOD2, APAF1, DAP3, STK3, and FAS (Figure 6A), it is unlikely that 
CCL2 alone entirely mediates the NFAT5 promotion of RA macro-
phage survival. Multiple genes governed by NFAT5 may coopera-
tively contribute to this process.
NFAT5 has been implicated in the pathogenesis of autoimmune 
diseases, particularly in RA (22). We have uncovered a crucial role 
for NFAT5 in the development of autoimmune chronic arthritis (22). 
NFAT5 is highly expressed in the synovia of patients with RA and 
tion, synovial hyperplasia, and bone destruction were less severe 
in mice injected with Nfat5+/– macrophages than in mice with 
Nfat5+/+ macrophages (Figure 10D). These results indicate that 
NFAT5-deficient macrophages are more susceptible to apoptosis 
in vivo and are therefore less efficient at promoting joint destruc-
tion than are NFAT5-sufficient macrophages. Collectively, it can 
be suggested that NFAT5 in macrophages is necessary for the pro-
gression of chronic arthritis.
Discussion
Macrophages possess broad proinflammatory, destructive, and 
remodeling capabilities and actively participate in the perpetua-
tion of chronic inflammation and joint destruction in RA (7, 8). In 
RA synovia, the number of synovial macrophages is positively cor-
related with disease activity (10, 11). Moreover, a change in syno-
vial sublining macrophages is a sensitive biomarker for response 
to antirheumatic treatment in patients with RA (16). Also, elimina-
tion of macrophages by clodronate-containing liposomes induc-
es long-term amelioration of rat adjuvant arthritis (35). A single 
intra-articular administration of clodronate liposomes decreases 
the expression of adhesion molecules in the synovial lining in RA 
patients, which correlates with macroscopic synovitis and C-reac-
tive protein levels (21). Evidence is also emerging that the apop-
totic death of activated macrophages is an important mechanism 
for controlling inflammation (36) and that dysregulated apoptosis 
can be one of the major pathogenic mechanisms responsible for 
RA pathology (12, 14). As such, the identification of key molecules 
that regulate the apoptosis and survival of macrophages may hold 
promise for the development of antimacrophage therapy for RA.
Through global gene expression profiling, we demonstrated 
that macrophage apoptosis, survival, and proliferation were the 
major pathologic processes represented by the DEGs in RA macro-
phages and NFAT5-deficient RAW 264.7 macrophages. Functional 
experiments in vitro showed that NFAT5 influenced the apoptotic 
death and proliferation of these cells. Interestingly, transcriptomic 
analysis of RA macrophages revealed that NFAT5 is a key TF in 
RA macrophage pathology and may have greater significance than 
NF-κB in RA pathogenesis. Indeed, NFAT5 expression was higher 
in RA macrophages than in normal macrophages differentiated 
from peripheral monocytes. Moreover, both NFAT5-deficient RA 
macrophages and mouse macrophages had higher rates of apop-
totic death upon starvation or treatment with apoptosis-inducing 
CHX, SNP, and/or TG than did NFAT5-sufficient macrophages. 
Taken together, these results suggest that expression levels of 
NFAT5 and its target genes are increased in RA macrophages and 
play an essential role in the antiapoptosis and survival of macro-
phages in both human and murine systems. Given the importance 
of macrophage survival in RA progression (10–12, 14), NFAT5 inhi-
bition, for example, via shRNA or small-molecule intervention, 
may retard RA progression by leaving macrophages more vulner-
able to apoptosis.
To explore the possible mechanisms for increased NFAT5 
expression in RA macrophages, we hypothesized that, since 
ambient proinflammatory and hypoxic stimuli are abundant in 
RA joints, they might also be contributing to increased levels of 
NFAT5 in RA macrophages. Our study demonstrated that NFAT5 
could be activated by factors other than hypertonicity and that 
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(tocilizumab, 8.6%). Comparisons were made with 96 healthy controls 
(16 men and 80 women) who had no rheumatic diseases. The mean age 
of the healthy controls was 56.8 ± 10.2 years. There was no difference in 
age or sex between RA patients and healthy controls.
Generation of NFAT5-deficient cells. RAW 264.7 macrophages were 
obtained from the Korean Cell Line Bank (Seoul National University, 
Seoul, Republic of Korea). NFAT5-deficient RAW 264.7 macrophages 
were generated by stable transduction of Nfat5 shRNA (NFAT KD) or 
by stable transfection of an NFAT5 decoy, as described previously (2) 
and as detailed in the Supplemental Methods.
Isolation of primary human and mouse macrophages. Monocytes/mac-
rophages were obtained from PBMCs of healthy controls or RA patients 
using anti-CD14 magnetic beads (Miltenyi Biotec) according to the man-
ufacturer’s instructions. To induce differentiation into macrophages, 
monocytes from healthy controls were cultured with M-CSF (20 ng/ml) 
for 48 hours and then stimulated again for 24 hours with IL-4 (20 ng/ml) 
for M2 macrophages or with IFN-γ (20 ng/ml) plus LPS (100 ng/ml) for 
M1 macrophages. RA synovial macrophages were freshly isolated from 
SFMCs of RA patients using anti-CD14 magnetic beads. In some exper-
iments, mouse peritoneal macrophages were isolated from the peritoneal 
fluid of WT Nfat5+/+ or Nfat5+/– mice 3 days after inducing acute inflam-
mation by injection of 3% sterile thioglycollate solution (BD Bioscienc-
es), as described previously (45). Primary mouse macrophages were also 
obtained from splenic cells 1 day after i.p. injection of LPS (10 mg/kg).
Microarray analysis. Total RNA was prepared using the RNeasy 
Mini Kit (QIAGEN), and RNA integrity was assessed using the Bio-
analyzer 2100 (Agilent Technologies). The RNA integrity number 
(RIN) was near 10 for all samples (data not shown). RNA was then 
amplified and hybridized to the Illumina MouseWG-6 version 2.0 for 
mouse RAW 264.7 macrophages or to the Illumina Human Ref-8 ver-
sion 3 Expression Bead Chip for human macrophages, according to the 
manufacturer’s standard protocols. Probe intensities were normalized 
using the quantile normalization procedure (46). The microarray data 
were deposited in the NCBI’s Gene Expression Omnibus (GEO) data-
base (GEO GSE76554 and GSE49604).
Empirical hypothesis testing. A permutation test strategy was used 
to determine the significance of overlap between DEGs in RA-SF mac-
rophages and NFAT5 target genes in RA-FLS and/or HUVECs. A total 
of 100,000 random permuted samples were used to compute the 
empirical P values of the overlapping DEGs.
qRT-PCR. Total RNA was subjected to cDNA synthesis using the 
RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. 
qRT-PCR was performed in a MyCycler (Bio-Rad) using SYBR Premix 
(Bio-Rad) according to the manufacturers’ instructions. GAPDH was 
used as the internal control for PCR amplification. Transcript levels were 
calculated relative to those of the controls and are expressed as –ΔΔCt. 
The gene-specific primers used are listed in Supplemental Table 1.
ELISA for CCL2. The level of CCL2 in the culture supernatant 
was measured with an ELISA kit (R&D Systems) according to the 
manufacturer’s recommendations. The detection threshold limit for 
CCL2 was 7.8 pg/ml.
Cell proliferation assay. The cell proliferation rate was measured 
using a BrdU Proliferation Assay Kit (Roche Diagnostics) according 
to the manufacturer’s instructions. Manual cell counts were also per-
formed after trypan blue exclusion.
Determination of cell viability and apoptosis. Cell viability was 
determined by MTT assay (Sigma-Aldrich) as described previously 
regulates synoviocyte proliferation and angiogenesis, a pathologic 
hallmark of RA (22). NFAT5-deficient mice show a marked reduc-
tion in anti–type II collagen Ab–induced arthritis (22). A study has 
also shown that partial loss of NFAT5 leads to lymphoid hypocellu-
larity and impaired antigen-specific Ab responses (2). Most recent-
ly, it has been shown that high salt promotes the differentiation of 
CD4+ T cells into Th17 cells, important cells in the pathogenesis of 
autoimmune diseases, via the NFAT5 pathway and enhances the 
production of pathogenic Th17–related cytokines and chemokines 
(42). In the present study, we discovered what we believe to be a new 
role for NFAT5 in the progression of arthritis by showing that NFAT5 
deficiency reduced macrophage infiltration and bone destruction in 
the mBSA/IL-1β–induced arthritis model, a chronic arthritis mod-
el in which macrophages play a central role (34). Additionally, we 
found that NFAT5-deficient macrophages were more susceptible to 
apoptosis and less efficient at promoting joint destruction than were 
NFAT5-sufficient macrophages. Together, our work provides, to our 
knowledge, the first direct evidence in vivo that NFAT5 expression 
in macrophage enhances chronic arthritis by conferring apoptotic 
resistance to activated macrophages.
In summary, through global transcriptomic profiling of 
NFAT5-deficient RAW 264.7 macrophages and RA-SF macro-
phages, we have identified an NFAT5-centered molecular network 
that defines the antiapoptosis, survival, and proliferation of macro-
phages. Transcriptomic analysis revealed that NFAT5 is a key TF gov-
erning pathologic processes in RA macrophages and showed a more 
significant overlap between its regulon and DEGs than did TP53 
or NF-κB complexes. Proinflammatory M1-polarizing stimuli and 
hypoxic conditions contribute to the enhanced NFAT5 expression 
seen in RA macrophages. Functional studies in vitro demonstrated 
that NFAT5 promotes survival and prevents apoptosis in both human 
and murine macrophages. CCL2, a chemokine, is critically involved 
in macrophage survival, acting as a representative downstream tar-
get of NFAT5. Moreover, NFAT5 expression in macrophages is nec-
essary for the progression of chronic arthritis in mice. Our data sug-
gest that NFAT5 regulates macrophage survival by inducing CCL2 
secretion and thereby plays a central role in the pathogenesis of mac-
rophage-dependent chronic inflammatory diseases such as RA. We 
anticipate that our systems approach to rheumatoid synovitis may 
serve as a comprehensive basis for further study of the fundamental 
mechanism(s) underlying activated macrophages in the pathogene-
sis of chronic inflammatory diseases.
Methods
Patients. One hundred seven patients who fulfilled the 1987 revised cri-
teria of the American Rheumatism Association for RA (43) were studied. 
Clinical information was available for 104 (97.2%) patients. The mean 
age of the 104 RA patients (13 men and 91 women) was 57.9 ± 11.6 years. 
The mean disease duration was 1.87 ± 0.33 years. A total of 85 (81.7%) 
of 104 RA patients were positive for rheumatoid factor and 91 patients 
(87.5%) were positive for the anticyclic citrullinated Ab. Eighty-two 
(78.8%) patients had erosions on hand and foot x-rays. The mean dis-
ease activity, as assessed by the disease activity score 28 (DAS28) (44), 
was 3.55 ± 1.27. All RA patients were treated with disease-modifying 
antirheumatic drugs (DMARDs) including methotrexate (77.9%), anti-
malarial drugs (50.0%), leflunomide (50.0%), sulfasalazine (13.5%), 
bucillamine (8.6%), anti–TNF-α Ab (6.7%), and anti–IL-6 receptor Ab 
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Additional methods, including reagents and Abs, Western blot 
analysis for NFAT5, BCL-2, BAX, and cleaved caspase 8, immuno-
fluorescence staining for NFAT5 and CCL2 expression, generation of 
BMDMs, histological assessment of arthritis, and statistical analyses 
are described in the Supplemental Methods.
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(47). Apoptosis of macrophages was assessed by flow cytometry using 
an FITC–Annexin V Apoptosis Detection Kit (Santa Cruz Biotechnolo-
gy Inc.) according to the manufacturer’s instructions.
Flow cytometric analysis for NFAT5 and CCL2. Intracellular 
expression of NFAT5 or CCL2 in macrophages was detected by 
flow cytometry. In brief, cells were stained with PE-conjugated Ab 
against anti-human CD14 Ab for 1 hour, fixed, and then made per-
meable with a commercially available permeabilization kit (eBio-
science). For measurement of intracellular NFAT5 expression, 
the cells were incubated with rabbit anti-human NFAT5 Ab for 1 
hour and then stained with an APC-conjugated secondary Ab for 
30 minutes. Cells were stained with APC-conjugated anti-human 
CCL2 Ab for 1 hour to determine intracellular CCL2 expression. 
APC-conjugated goat IgG and APC-conjugated mouse IgG1κ were 
used as isotype-matched Abs. Fluorescence was measured using 
the FACS Canto II Flow System (BD Biosciences), and the data 
were analyzed using FlowJo software (Tree Star).
Induction of mBSA/IL-1–induced arthritis. Eight-week-old het-
erozygous NFAT5+/– mice and their WT NFAT5+/+ littermates were 
used in the in vivo experiments. Following previously published 
protocols (34, 48), 10 μl (20 mg/ml) mBSA (Sigma-Aldrich) was 
singly injected into the knee joint on day 0, followed by a daily s.c. 
injection of 20 μl (250 ng) IL-1β (R&D Systems) into the ipsilateral 
footpad on days 1 through 3.
Study approval. This study was performed with the approval of 
the IRB of Seoul St. Mary’s Hospital (Seoul, Republic of Korea; CUM-
C09U034). All patients and healthy volunteers provided written 
informed consent to participate in the study.
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